The cell therapy industry would greatly benefit from a simple point of care solution to remove 25 Dimethyl Sulfoxide (DMSO) from small volume thawed cell suspensions prior to injection. We have 26 designed and validated a novel dead-end filtration device, which takes advantage of the higher density 27 of thawed cell suspensions to remove the DMSO and protein impurities from the cell suspension 28 without fouling the filter membrane. The filter was designed to avoid fluid circuits and minimize the 29 surface area that is contacted by the cell suspension, thus reducing cell losses by design. 30
The cell therapy industry would greatly benefit from a simple point of care solution to remove 25 Dimethyl Sulfoxide (DMSO) from small volume thawed cell suspensions prior to injection. We have 26 designed and validated a novel dead-end filtration device, which takes advantage of the higher density 27 of thawed cell suspensions to remove the DMSO and protein impurities from the cell suspension 28 without fouling the filter membrane. The filter was designed to avoid fluid circuits and minimize the 29 surface area that is contacted by the cell suspension, thus reducing cell losses by design. 30
The filtration process was established through optimization of the fluid flow configuration, backflush 31 cycles and filter geometry. Overall, this novel filtration device allows for a 1 mL of thawed 32 cryopreserved cell suspensions, containing 10 7 cells of a foetal lung fibroblast cell line (MRC-5), to 33 be washed in less than 30 minutes. More than 95% of the DMSO and up to 94% of the Albumin-34
Fluorescein-Isothiocyanate content can be removed while the viable cell recovery is higher than 80%. 35
We have also demonstrated that this system can be used for bone marrow-derived human 36 mesenchymal stem cells with more than 73% cell recovery and 85% DMSO reduction. This is the first 37 time that a dead end (normal) filtration process has been used to successfully wash high density 38 human cell suspensions. In practice, this novel solid-liquid separation technology fills the need for 39 small volume washing in closed processing systems for cellular therapies. 40 41 F o r P e e r R e v i e w
Introduction 43
The cryopreservation of cellular therapy products is usually performed by controlled-rate freezing (1-44 5°C/min) in the presence of DMSO, which is the prefered cryopreservation agent (CPA) in virtually 45 every cryopreservation solution (Rowley 2009 ). This is due to its efficient diffusion across the cell 46 membrane coupled with the ability to prevent intracellular ice formation and osmotic stress during 47 slow rate freezing (Mazur 1984) . In the treatment of blood disorders the cell product may be infused 48 to patients without any reduction in DMSO concentration even though the presence of this CPA has 49 been shown to cause nausea, vomiting, cardiac arrhythmia (Cox et al. 2012 ) and, less frequently, more 50
severe adverse reactions such as neurotoxicity (Abdelkefi et al. 2009 ), cardiac arrest or epileptic 51 seizure (Cox et al. 2012) . Thus, safety concerns are raised when the cellular product consists of a 52 small volume (<10 mL) cell suspension which will be injected into a solid tissue such as the brain or 53 heart (FDA 1997) . Such an injection is likely to expose the patient's cells to a much higher DMSO 54 concentration than a blood stream infused product. Although there is no safety data for concentrated 55 DMSO injections in humans, there is published work in animals (Galvao et al. 2014 ) and brain tissue 56 culture (Tamagnini et al. 2014) . These data strongly suggest that a reduction in DMSO concentration 57 is required for cell therapies which are administered via injection into solid tissues and should be 58 performed even in infused cell therapies. 59
To reduce the DMSO concentration in thawed cell suspensions the most common process is open lab 60 centrifugation. This process is only acceptable in a laminar flow chamber placed in a grade B 61 cleanroom background, which represents an unacceptable financial burden for the current Point of 62 Care (POC) sites such as hospitals or clinics that do not have a cell-processing facility. Another 63 solution is the use of closed centrifugal systems such as the COBE 2991 (Terumo BCT, Colorado, 64 USA) or Sepax S-100 devices (Biosafe S.A., Eysins, Switzerland). These can be used to separate 65 mononuclear cells from red blood cells or as cell washing devices, reaching 97% removal of the 66 DMSO content (Rodríguez et al. 2004 ) and a total nucleated cell recovery of 75% in cryopreserved 67 peripheral blood progenitor cell products for autologous infusion (Sánchez-Salinas et al. 2012) . While 68 these centrifuge-based systems are efficient, they are expensive and not amenable to small scale cell 69 F  o  r  P  e  e  r  R  e  v  i  e  w F  o  r  P  e  e  r  R  e  v  i  e  w 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  P  e  e  r  R  e  v  i  e  w   6 cold (2-8 °C) CryoStor™ containing 5% v/v of DMSO (CS5, BioLife Solutions, WA, USA) to yield 1 126 mL single cell suspension containing 10-20 million cells/mL. This cell suspension was dispensed into 127 3 mL Crystal™ vials (Aseptic Technologies, Belgium), incubated for 10 minutes on ice and then 128 transferred to a -80 °C freezer where it was cooled at an approximate rate of -1 °C/min, using a 129
CoolCell container (BioCision, CA, US) and kept up to a maximum of 1 month before use. 130
Device design and operation 131
The filter devices were designed using AutoCad 2011 (Autodesk, CA 94903, USA) and manufactured 132 by machining in UCL's Biochemical Engineering workshop, using either Poly(methyl methacrylate) 133 (PMMA) or Stainless Steel 316 (SS) as a the base material, and by injection molding using the 134
Protomold service from Protolabs, UK. The base material used for injection molding was Cyclic 135
Olefin Co-polymer (COC). 136
All the devices were designed to allow the 1 mL thawed cell suspension to form an undisturbed bed 137 while the washing buffer flowed through the cell suspension. This configuration minimized and 138 delayed the progressive filter clogging typical in a dead end filtration process. The design shown in 139 Figure 1A enabled the formation of this cell bed by localizing the filter membrane above the cell 140 suspension and ensuring that the lower chamber had a higher volume than that same loaded cell 141 suspension, such that during the wash operation there was a decreasing cell concentration from the top 142 surface of the cell bed to the filter membrane ( Figure 1B, top) . The wash step was performed by 143 flowing wash buffer (PBS) from the bottom and lateral inlets of the lower chamber ( Figure 1B, top) . 144
The semi-conical shape of this chamber was designed to enable the post wash gas phase volume 145 reduction of the cell suspension: this shape stabilizes an injected air bubble which occupied the top 146 part of the bottom chamber, leaving behind a volume reduced cell suspension ( Figure 1B , middle) that 147 was collected directly into a syringe ( Figure 1B , bottom); these process steps are shown in the 148 supplementary movies S1-3 (A with dye and B with cells) and S4. The fixed process inputs and 149 parameters are listed in Table I ; the operating temperature was kept at 21 ± 2°C. 150
Cell counts 151
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DMSO measurement 156
The concentration of DMSO in the filtrate and retentate was measured by reverse phase high 157 performance liquid chromatography (HPLC) using an Agilent 1200 series device (Agilent 158
Technologies UK Limited) under the control of the Agilent Chemstation software. A 4 mm x 125 mm 159 (internal diameter x length) Nucleosil C18 column with a particle size of 5 µm (Sigma-Aldrich, UK) 160 was used as the stationary phase, while the mobile phase was based on a previously published 161 protocol (Thumm et al. 1991) . Briefly, an aliquot was taken from the filtrate or retentate sample and 162 diluted 1:20 in 0.1% (v/v) Trifluoro Acetic Acid (TFA, Sigma-Aldrich UK). Calibration curves of CS 163 5 were prepared at the appropriate dilution and analyzed in parallel with the samples. The elution 164 profile consisted of 100% distilled water in the first 5 min followed by a linear gradient of 165 water/acetonitrile until 100% of acetonitrile was reached at 7 min; the reverse gradient was applied to 166 reach 100% water at 9 min and maintained until 15 min. The DMSO peak was detected (210 nm 167 detection wavelength) at 3-5 min of elution time. All results are presented as the ratio బ , where C and 168 C 0 are the final and initial concentration of DMSO, respectively. 169
FITC-Albumin experiments and quantification 170
To assess the removal of larger molecular weight molecules, 20 µL of conjugated Albumin-171 Fluorescein Isothiocyanate (FITC) (A9971, Sigma UK) at a concentration of 5 mg/mL in CS 5 were 172 added to the 1 mL cell suspension immediately after thaw and before the filtration process. The 173
Albumin-FITC concentrations were measured using a FluoStar Optima microplate reader (excitation 174 450 nm, emission 544 nm). Calibration curves of Albumin FITC in CS 5 were prepared at the 175 appropriate dilution and analyzed in parallel with the samples. All results are presented as the ratio బ , 176
where C and C 0 are the final and initial concentrations of FITC-Albumin, respectively. 177
Pressure Measurements 178
The pressure in the lower chamber of the system was measured against the atmospheric pressure using 179 either a manual or a digital manometer with data-logging capabilities (Sper Scientific, AZ US 
where F is the flow rate in mL/min, t is time in min, V C is the lower (cell-containing) chamber 184 volume, N is the number of diavolumes, defined as the quocient between the total volume used for 185 filtration and the volume of the filtration chamber, and k is a wash efficiency parameter which is 186 dependent on the geometry of the device. Bioscience, Oxford, UK). Flow cytometery was performed using a BD LSR II flow cytometer. For 216 analysis, at least 50,000 events were initially gated based on forward and side scatter and forward 217 scatter height against area was used for doublet removal. The isotype control cocktail was run with the 218 same gating strategy and MSCs defined from gating the top 1% of isotype expression. To confirm an 219 MSC phenotype, greater than 95% expression of CD105, CD90, CD73, and less than 2% expression 220 of CD14, CD20, CD34 and CD45 must be observed (Dominici et al. 2006 ). N=3 samples were run 221 and the standard deviation calculated. 222
Statistics 223
The statistical analysis was performed using the Excel data analysis add-on and the GraphPad 224 software. The p-values presented were calculated for the two tails of the normal distribution and when 225 more than 2 groups were compared Tukey's multicomparison test was used. The notation "n" 226 (lowercase, not to be mistaken by uppercase "N", the diavolumes) was used to denote the number of 227 independent replicates. 228
Results

229
To test this new filtration device it was necessary to choose a filter medium and a pore size which 230 minimized the rate of pressure increase during the wash operation; initial tests demonstrated that a 231 hydrophilic Polyvinylidene fluoride (hPVDF) with a nominal pore size of 0.65 µm was a feasible 232 starting point (data not shown). 233 To maximize the number of cells recovered, it was hypothesized that a backflush step between the 234 wash and concentration steps would dislodge cells from the filter membrane and increase the post 235 process VCR. The wash step was performed using a flow rate of 2 mL/min via the bottom inlet and 5 236 mL/min through the lateral inlet (2/5 flow). While no significant difference in VCR was observed 237 when this backflush step was present (compared to its absence), there were significant effects on the 238 amount of solute removed. Figure 2A depicts the DMSO concentration in the filtrate over time, and it 239 is visible that after the backflush step there is an increase in the DMSO concentration in the filtrate. It 240 was hypothesized that the overall DMSO removal of the retentate could be enhanced if several 241 backflush steps were applied during the wash phase. Figure 2B depicts the experimental design used 242 to test this hypothesis, where 3 backflush steps were performed during a 2/5 wash for 10 min (3x 243 backflush) and compared with a 10 min 2/5 wash with one backflush step after the wash operation (1x 244 backflush). Figure 2C shows that the 3x backflush wash yielded a lower DMSO concentration than 245 the 1x backflush wash, with 0.136 ± 0.003 and 0.20 ± 0.01 of the initial DMSO concentration, 246 respectively (n=3, p<0.001). This increase in DMSO removal was also associated with a higher lower 247 chamber pressure in the 3x backflush wash when compared with the 1x backflush wash, after 10 248 minutes, as shown in Figure 2D . 249
The individual contributions of the bottom and lateral flows for the DMSO removal from the cell 250 suspension were investigated. Figure 3 shows that, after a 10 minutes wash period, the lateral flow 251 reduces the initial amount of DMSO to 0.66 ± 0.09 (n=5) of its initial concentration. There was no 252 significant difference between the concentration of DMSO after the bottom flow wash and the 253 lateral+bottom (2/5) flow wash (0.25 ± 0.01, n=3 and 0.17 ± 0.06, n=3), for the 10 min wash period. 254
However, the presence of a bottom flow results in a significantly higher DMSO reduction when 255 compared to using lateral flow only (p<0.01). 256
The combinatorial effect of the lateral and bottom flows (2/5 flow) on DMSO reduction was further 257 investigated as a function of the diavolumes N (Bottom Flow x Time), as shown in Figure 4A To be useful as part of a point of care device, this filter will be manufactured as an injection molded 264 part, like most medical devices or bioprocessing consumables. The panels C and D in Figure 4 depict 265 a PMMA filter device which houses an injection molded (IM) COC lower chamber whose shape is 266 identical to the one in Figure 1A . This IM device was used to process thawed MRC-5 cell suspensions 267 at 2 mL/min bottom flow, without lateral flow, for 24 min and the volumes, cell concentration and 268 DMSO removal are shown in Table 2 . The DMSO reduction for this data was 91 ± 2% for N=32, as 269 shown in Figure 4A . The cell recovery and volume reduction was 84 ± 1% and 2.7 ± 0.5 fold, 270
respectively. These results demonstrate that this filtration system can be successfully used for small 271 volume cell suspension wash and volume reduction, with a cell recovery of more than 80%. 272
Moreover, the use of a thermoplastic material indicates that the performance of the PMMA device is 273 close to the performance of the consumable. 274
The filtration device was redesigned to increase the DMSO reduction while avoiding pressure build-275 up in the lower chamber, i.e. increasing the wash without using the lateral flow. Figure 5A shows the 276 3 geometries of the filtration device, where M1 (mark 1) is the original design, with a lower chamber 277 height (bottom inlet to filter membrane) of 0.8 cm and a filtration area of 3.5 cm 2 . To minimize the 278 diffusional distances and increase the fluid velocity, the M2 geometry was designed to increase the 279 height of the chamber by 50% (compared to M1) while maintaining a constant volume, thus 280 decreasing the cross sectional area of the bottom flow chamber. This was achieved by changing the 281 chamber from a round bottom to a V-bottom shape. Computational fluid dynamics (CFD) was used to 282 model DMSO removal in M2 under the 2/5 flow configuration; the surface plot in figure 5B depicts 283 the top view of the M2 device and it indicates that there is accumulation of DMSO in the outer area of 284 the membrane. Again, these areas are the furthest away from the bottom flow jet and they could be 285 designed out (or "trimmed" out) of the M2 geometry thus yielding the M3 geometry, with a 2.5 cm 2 286 area (30% decrease vs M2) and a lower chamber height of 1.5 cm (25% increase vs M2). These 287 geometry changes had significant effects on the DMSO removal rate, as demonstrated in Figure 5C . 288 When using only the bottom inlet to flow wash buffer through the cell suspension (solid lines) it is 289 geometries, their DMSO reduction curves also fit a single exponential decay (solid lines, R 2 =0.97 for 293 both). However, the M3 geometry, operating with bottom flow only, sustains the lower chamber 294 pressure below 15 mbar, whereas the M1 and M2 geometries, operating with the 2/5 flow, can reach 295 pressures of 100 and 400 mbar, respectively ( Figure 5D, n=3) . These data indicate that the M3 296 geometry enables an efficient DMSO reduction while operating at low pressures. 297
To further validate the hypothesis that the diffusional distance is the critical factor behind these 298 increases in efficiency from M1 to M3, the differences in these geometries were factored into 299 Equation 1. By keeping the volume of the chamber constant and increasing the height of the chamber, 300 the whole shape becomes "thinner" along its length thereby reducing the diffusional distance and 301 increasing the fluid velocity. As such, the increase in height is proportional to the increase in the 302 amount of DMSO removed. To incorporate this into equation 1 it should be noted that the effect of the 303 height implies that for the same level of DMSO removal, less diavolumes (N) are needed as the height 304 is increased. In this way, N should be replaced by the product N×height. However, since this is an 305 exponential term it must be dimensionless. Since N is dimensionless so should the height be; to 306 achieve this it was noted that height=sin(α)×longer slope (as per figure 5E ) and the sin(α) was used 307 instead of the height. Thus, Equation 1 can be modified to: 308
The semi-logarithmic plot of బ vs ܰ × sin ߙ is depicted in Figure 5F . This plot shows that the data 309 points derived from Equation 1 in Figure 5C 
98). 311
The M3 geometry was further characterized by its ability to reduce the amount of a model protein, 312 albumin-FITC; After a 32 diavolumes wash the initial concentration of this protein was reduced by 94 313 ± 1% ( Figure 5G) . Furthermore, the viable cell recovery using M3 was 94 ± 5%, thus confirming that 314 this geometry also enables a high cell recovery, while the volume reduction was 1.55 ± 0.08 fold 315 (Table 2) . To assess the functionality and long-term viability of the cells after being processed, the 316 M3 geometry was manufactured in stainless steel 316. Figure 5H demonstrates that, after a 16 317 diavolumes wash, the MRC-5 cell line still grows at the same specific rate as fresh cells or cells which 318 have also been thawed but processed using a bench top centrifuge (see methods). Importantly, cell 319 counts after a 24 hour culture showed that after thawing, processing and plating 62 ± 15% of the cells 320 (post thaw counts) survived; when no cell processing was performed and cells were directly plated in 321 adherent flasks, the cell recovery was 58 ± 5% (n=4). 322
To validate this geometry for cell therapy applications, hMSCs were processed using the M3 323 geometry filtration device. The post filtration characterization of these cells was performed according 324 to the ISCT criteria (Dominici et al. 2006 ) and the 3 cell runs (generated from 2 donors) showed that 325 hMSCs retained their characteristic surface markers ( Figure 6 A and B), while retaining their ability 326 to adhere to plastic, proliferate ( Figure 6E and F) and the capability for chondrogenic, osteogenic and 327 adipogenic differentiation ( Figure 6G, H and I ). The viable cell recovery after these 3 runs ranged 328 from 73 to 99%, while the DMSO removal ranged from 86-88% ( Figure 6 C and D) . 
Discussion
330
In this work, we have designed and characterized a filtration system to process thawed cell 331 suspensions which removes more than 90% of the DMSO and recovers more than 80% of the viable 332 cells. Most importantly, this filtration system does not require an outside loop like a TFF system, thus 333 minimizing the shear stress that cells are exposed to and the area where liquid can be lost by 334
adsorption. 335
The central element of the filter housing design ( Figure 1A) is the laminar flow that is established at 336 these dimensions and flow velocities. While it is visible that the cell suspension has settled at the end 337 of the filtration process, it is unlikely that cell settling can be faster than the flow rate of wash buffer 338 from the bottom inlet. The average linear velocity of wash buffer crossing the membrane from the 339 bottom flow is 0.57 cm/min while the average cell settling velocity is at least one order of magnitude 340 below this velocity (Chalmers et al. 1999 ). Another possibility is that the settling velocity of the cells 341 is increased in the Cryostor media; while this is true in absolute terms, because the CS5 is hypertonic, 342 F o r P e e r R e v i e w 14 it is the density difference between the cells in CS5 and the CS5 medium that is relevant for the 343 settling velocity. Thus, it is expected that the density differences between fresh cells in PBS and 344 thawed cells in CS5 are the same; this was confirmed by an isopycnic centrifugation using a Percoll 345 gradient (Supplementary Figure 1) which confirmed that the density of the MRC-5 cells in CS5 is 346 between 1.04 and 1.06 g/mL, whereas the literature reports a similar density for these cells in PBS 347
(1.05 g/mL) (Birnie and Rickwood 1980) . 348
Using the lateral flow configuration, the DMSO concentration was reduced to 0.66 of its initial value 349 ( Figure 4) ; interestingly, this value is the same as the ratio of the cell suspension volume to the lower 350 chamber volume (1mL/1.5mL), which strongly suggests that the lateral flow alone does not remove 351 any significant amount of DMSO after 10 minutes. Nevertheless, the addition of lateral flow to the 352 bottom flow (2/5 flow) seems to provide a more efficient mixing for both M1 and M2 geometries, and 353 thus a better reduction in DMSO concentration, when compared with using the bottom flow only 354 ( Figure 5C ). These results follow the same trend as the use of increased backflush cycles to enhance 355 DMSO reduction (Figure 2) , also at the expense of higher pressure differences. Taken together, these 356 two data sets strongly suggest that both the lateral flow and the backflush cycles increase the DMSO 357 removal, by dispersing the cell bed that is established if bottom flow only is used. The design changes 358 that lead to the M3 geometry had the goal of avoiding the dispersion of the cell bed that results in 359 increased lower chamber pressures This was accomplished by prioritizing the minimization of the 360 average diffusional length and the maximization of the fluid velocity. The M3 geometry, while having 361 a lower volume reduction capability when compared to M1, does not require lateral flow to have a 362 single exponential wash profile, as described by equation 1, while washing more than 95% of the 363 DMSO using less diavolumes; using only one inlet to flow the wash buffer makes the operation 364 simpler and will decrease the manufacturing cost of the POC device. The empirical model described 365
by Equation 2 validates the aforementioned design hypothesis, as depicted in Figure 5F ; when the 366 DMSO removal curve fits equation 1, the different geometries can be normalized to the distance 367 between the filter membrane and the bottom flow inlet. Both the M1 and M2 geometries DMSO 368 removal data points shift to the right of the curve in Figure 5F when only bottom flow is used, a result 369 which can be explained by cell settling in a low shear environment. The M3 filtration device was also 370 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 The processing of hMSCs (Figure 6 ) demonstrated the capability of this novel filtration device for 374 small volume cell wash, using cells relevant for cell therapy. Despite the DMSO removal efficiency 375 being lower than for the MRC-5 cells wash, 88% of the DMSO was removed from hMSC cell 376
suspensions. This lower washing efficiency can be attributed to different biophysical characteristics, 377 namely cell size, and it is a clear area of research in the development of this technology. Another 378 point for future research is how to have sterility as a release criterion for the cellular therapies, since 379 this takes about 24h to be tested and the therapies need to be administered within minutes. 380
In a broader sense, a simple solid-liquid separation device for small volumes is a key enabling 381 technology to make the distributed manufacturing of cellular therapies possible. 382 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 This frame corresponds to t=1s in the wash process. 464 Figure 2 -DMSO removal is enhanced by backflush frequency. The filter device was operated for 10 465 min in the wash mode with a 2 mL/min bottom flow rate and a 5 mL/min cross flow rate; after this 466 wash step and before the concentration step a backflush was performed to dislodge cells from the 467 filter membrane (see methods). The concentration of DMSO in the collected filtrate fractions 468 increases after backflush (A). The backflush step was repeated 3 times throughout the wash period 469 (3xbackflush) and compared to a single backflush after the wash step (1xbackflush) (B) for the 470 amount of DMSO left in the cell suspension (lower chamber, which contains the retentate) (C) and the 471 pressure difference generated in the lower chamber (D). ***, p<0.001. 472 devices; when the number of diavolumes is multiplied by the sin(α), specific for each device, the 496 curves that obey equation1 in C follow a single exponential decay empirical model, as described by 497 equation 2 (F). The M3 geometry was assessed for its ability to reduce albumin-FITC by washing a 498 cell suspension for 24 minutes at 2mL/min bottom flow (G); furthermore, the cellular proliferation 499 after filtration processing, using the M3 geometry (n=4), was compared with post-centrifugation 500 processing (n=5) and fresh cell culture processing (i.e. cell counts during passaging, n=5) by 501 calculating the specific growth rate µ (day -1 ). 502 Figure 6 -hMSC post filtration recovery, proliferation and characterization. hMSCs were processed 503 using the M3 geometry filtration device. The post filtration characterization after 3 cell runs 504 (generated from 2 donors) was performed according to the ISCT criteria: cell surface markers ( Figure  505 6 A, individual flow cytometry histograms, and B, aggregate results from the 3 cell runs), adherence 506 to plastic ( Figure 6E , scale bar=400 mm) and the capability for chondrogenic, osteogenic and 507 adipogenic differentiation ( Figure 6G , H, scale bar=100 mm, and I, scale bar=50 mm, respectively). 508
The viable cell recovery, DMSO removal and hMSC growth rates after filtration are displayed in 509 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Filtration device design and fluid flow. A)-CAD drawing of the filtration device housing, divided in a top and bottom part (A, top); when the device is assembled (A, bottom) the filter is located between the two parts and the cell suspension is introduced into the bottom, where it is washed, concentrated and loaded into a syringe (B, Supplementary videos). Panel C) depicts the fluid flow in the device: for visualization purposes, a red dyed PBS solution was used to wash 1 mL of a (transparent) cell-free CryoStor5 solution (the full video is available in Supplementary Video S2A). This frame corresponds to t=1s in the wash process. 115x127mm (300 x 300 DPI) DMSO removal is enhanced by backflush frequency. The filter device was operated for 10 min in the wash mode with a 2 mL/min bottom flow rate and a 5 mL/min cross flow rate; after this wash step and before the concentration step a backflush was performed to dislodge cells from the filter membrane (see methods). The concentration of DMSO in the collected filtrate fractions increases after backflush (A). The backflush step was repeated 3 times throughout the wash period (3xbackflush) and compared to a single backflush after the wash step (1xbackflush) (B) for the amount of DMSO left in the cell suspension (lower chamber, which contains the retentate) (C) and the pressure difference generated in the lower chamber (D). ***, p<0.001. 160x94mm (300 x 300 DPI) Lateral flow wash alone shows a limited DMSO reduction. The filter device was operated for 10 minutes in the wash mode with a 2 mL/min bottom flow rate without cross flow (20 mL, n=3), with a 5 mL/min lateral flow rate without bottom flow (Lateral 5 mL/min, n=3) and with a 2 mL/min bottom flow rate and a 5 mL/min cross flow rate (2/5 flow, n=6 Synergistic effect of the lateral and bottom flows. The presence of lateral flow during cell washing yields a DMSO reduction profile described by a single exponential function, as predicted by equation 1 (A, closed squares, n≥3 for all data points), whereas in the absence of the lateral flow, the bottom flow wash does not fit the equation 1 model (A, closed circles, n≥3 for all data points). The typical pressure profiles for these 2 wash modes show that the presence of cross flow also leads to pressure build-up in the lower chamber, unlike the bottom flow only operation mode (B). To mimic the final thermoplastic product the bottom flow chamber geometry was injection molded (C, purple) to fit a PMMA housing (C, gray). 85x56mm (300 x 300 DPI) -Redesigning the filtration device for improved DMSO removal. The original filtration device was redesigned by changing the geometry of the bottom chamber which holds the cell suspension, which led to changes in the distance between the bottom inlet and the filter membrane, and filtration area (A). A CFD analysis on the M2 geometry revealed "dead zones" where the DMSO was being removed with less efficiency (B). The 3 different geometries were evaluated for their DMSO reduction capability (C, n≥3 for all data points), operated with (open symbols) and without (closed symbols) lateral flow, except for M3, where lateral flow lead to clogging (data not shown); the final pressure in the lower chamber, after 24 min, also revealed differences between geometries and wash modes (D, n=3 for all data points). The sine of the angle α, formed between the horizontal plane and the lower chamber slope that connects the bottom and lateral inlets (E), is different between devices; when the number of diavolumes is multiplied by the sin(α), specific for each device, the curves that obey equation1 in C follow a single exponential decay empirical model, as described by equation 2 (F). The M3 geometry was assessed for its ability to reduce albumin-FITC by washing a cell suspension for 24 minutes at 2mL/min bottom flow (G); furthermore, the cellular proliferation 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w after filtration processing, using the M3 geometry (n=4), was compared with post-centrifugation processing (n=5) and fresh cell culture processing (i.e. cell counts during passaging, n=5) by calculating the specific growth rate µ (day-1). 119x150mm (300 x 300 DPI) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 F o r P e e r R e v i e w hMSC post filtration recovery, proliferation and characterization. hMSCs were processed using the M3 geometry filtration device. The post filtration characterization after 3 cell runs (generated from 2 donors) was performed according to the ISCT criteria: cell surface markers (Figure 6 A, individual flow cytometry histograms, and B, aggregate results from the 3 cell runs), adherence to plastic ( Figure 6E , scale bar=400 µm) and the capability for chondrogenic, osteogenic and adipogenic differentiation ( Figure 6G , H, scale bar=100 µm, and I, scale bar=50 µm, respectively). The viable cell recovery, DMSO removal and hMSC growth rates after filtration are displayed in 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
